NEW YORK ( TheStreet) -- Biotech, biotech, biotech. That's been the talk of Wall Street for all of 2013, with mergers and acquisitions happening every other day. That's why TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed which biotechs could be the next to merge.Both Trius Therapeutics (TSRX) and Cubist Pharmaceuticals (CBST) are up by double-digit percentage points after their merger.
Cramer Quick Take: What's Next for Biotech?
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.